Why the FDA hearing on Vanda Pharmaceuticals’ HETLIOZ could reshape drug approval challenges
FDA grants rare hearing to review Vanda Pharmaceuticals’ HETLIOZ jet lag application. Discover what this regulatory fight could mean for circadian medicine.
Pillar Biosciences launches rapid AML sequencing panel while Creatv Bio liquid biopsy enters colorectal cancer trial biomarker role
Pillar Biosciences launches rapid AML sequencing panel as Creatv Bio liquid biopsy enters colorectal cancer trial. Explore what these tools mean for oncology research.
How Creatv Bio’s LifeTracDx may change immune biomarker tracking in colorectal cancer studies
Creatv Bio’s LifeTracDx joins CytoDyn’s Phase 2 colorectal cancer trial as a liquid biopsy biomarker tool. Discover what this means for oncology diagnostics.
Can lightweight AI models replace massive drug discovery systems? Insilico Medicine and Liquid AI think so
Insilico Medicine and Liquid AI unveil a lightweight AI model for drug discovery. Learn how smaller foundation models could reshape pharmaceutical research.
How Adela’s tissue-free ctDNA methylation test could reshape monitoring of immunotherapy outcomes
Adela’s methylome blood test may help detect immunotherapy response earlier in cancer care. Discover what the latest study reveals for clinicians and diagnostics markets.
Insightec’s focused ultrasound therapy secures French reimbursement. Could incisionless brain procedures expand across Europe?
France approves reimbursement for MR-guided focused ultrasound in essential tremor. Discover what the policy change means for neurosurgery and patient access.
Gazyva’s ALLEGORY data: what the SRI-4 and DORIS remission outcomes mean for lupus care
Genentech’s obinutuzumab met all ALLEGORY phase III endpoints in SLE. What the remission and flare data mean for lupus treatment strategy.
Could LifeVac redefine emergency choking response after failed basic life support protocols
FDA grants De Novo clearance to LifeVac as the first authorized anti choking device. Discover what this means for emergency airway care and medical device regulation.
Aisa Pharma’s AISA-021 shows mixed but promising signals in systemic sclerosis-associated Raynaud’s phenomenon
Aisa Pharma’s AISA-021 shows promising Phase 2 signals in systemic sclerosis Raynaud’s. Discover what the RECONNOITER data could mean for future treatment.
Can HR HealthCare’s EZ-Protect catheter reshape infection-prevention expectations in intermittent catheter care
HR HealthCare launches the EZ-Protect hydrophilic catheter line to reduce infection risk and improve portability. Discover what it means for urology care.